Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Cited by (1,000)

Items 301–400 of 1,000

1. Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study
   Tressie Herrmann, Angeline Ginzac, Ioana Molnar, Sébastien Bailly, Xavier Durando, Hakim Mahammedi · 2021 · Cancer Medicine
2. Polypharmacologic Reprogramming of Tumor-Associated Macrophages toward an Inflammatory Phenotype
   Nao Nishida‐Aoki, Taranjit S. Gujral · 2021 · Cancer Research
3. Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatment
   Tian Zhang, Daniel J. George · 2021 · Nature Medicine
4. Hypoxia-Inducible Factor in Renal Cell Carcinoma: From Molecular Insights to Targeted Therapies
   Giandomenico Roviello, Irene De Gennaro Aquino, Ismaela Anna Vascotto, Giulia Venturi, Alberto D’Angelo, Costanza Winchler, Adriana Guarino, Salvatore Cacioppo, Mikol Modesti, Marinella Micol Mela et al. · 2024 · Genes
5. Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?
   Eric W. Jonasch, Michael B. Atkins, Simon Chowdhury, Paul N. Mainwaring · 2022 · Cancers
6. Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma
   Matteo Santoni, Francesco Massari, Marc Ryan Matrana, Umberto Basso, Ugo De Giorgi, Gaetano Aurilio, Sebastiano Buti, Lorena Incorvaia, Mimma Rizzo, Angelo Martignetti et al. · 2022 · European Journal of Cancer
7. Next Wave of Targets in the Treatment of Advanced Renal Cell Carcinoma
   Luisa M. Cardenas, Jasna E. Deluce, Shahrukh Khan, Omar Gulam, Saman Maleki Vareki, Ricardo Fernandes, Aly‐Khan A. Lalani · 2022 · Current Oncology
8. Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT)
   Xinan Sheng, Dingwei Ye, Aiping Zhou, Xin Yao, Hong Luo, Zhisong He, Zengjun Wang, Yingchao Zhao, Zhigang Ji, Qing Zou et al. · 2022 · European Journal of Cancer
9. Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations
   Kelly N. Fitzgerald, Cihan Düzgöl, Andrea Knežević, Natalie Shapnik, Ritesh R. Kotecha, David Henry Aggen, Maria Isabel Carlo, Neil J. Shah, Martin Henner Voss, Darren Richard Feldman et al. · 2022 · European Urology
10. Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study)
    Atsushi Nakamura, Ou Yamaguchi, Keita P. Mori, Keita Miura, Motohiro Tamiya, Tomohiro Oba, Noriko Yanagitani, Hideaki Mizutani, Takashi Ninomiya, Tomosue Kajiwara et al. · 2023 · European Journal of Cancer
11. Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma
    Alex Chehrazi‐Raffle, Ramya Muddasani, Nazlı Dizman, Joann Hsu, Luís Meza, Zeynep Büşra Zengin, Jasnoor Malhotra, Neal Shiv Chawla, Tanya Barauskas Dorff, Tania Contente‐Cuomo et al. · 2023 · JCO Precision Oncology
12. A systematic review and meta-analysis on the optimal treatment duration of checkpoint inhibitoRS in solid tumors: The OTHERS study
    Giorgio Bogani, Michela Cinquini, Diego Signorelli, Elio Gregory Pizzutilo, Rebecca Romanò, Melissa Bersanelli, Daniele Raggi, Salvatore Alfieri, Sebastiano Buti, Federica Bertolini et al. · 2023 · Critical Reviews in Oncology/Hematology
13. Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022
    Yanfeng Wang, Chanjuan Cui, Lei Deng, Lin Wang, Xiayang Ren · 2023 · Frontiers in Immunology
14. Elevated eosinophils proportion as predictor of immune‐related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma
    Yoshihiko Tasaki, Shuzo Hamamoto, Yosuke Sugiyama, Nami Tomiyama, Taku Naiki, Toshiki Etani, Kazumi Taguchi, Nayuka Matsuyama, Yasuhito Sue, Yoshihisa Mimura et al. · 2023 · International Journal of Urology
15. Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study
    Hui‐min Lian, Jia-liang Wu, W.J. Liufu, Tiantian Yu, Shaoqing Niu, Yong Bao, Fang Peng · 2024 · Cancer Immunology Immunotherapy
16. Von Hippel-Lindau tumor suppressor pathways & corresponding therapeutics in kidney cancer
    Maxwell Shulman, Rachel Shi, Qing Hua Zhang · 2021 · Journal of genetics and genomics/Journal of Genetics and Genomics
17. Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab
    Landon Carter Brown, Kunal B. Desai, Wei Wei, Emily Noelle Kinsey, Chester Kao, Daniel J. George, Brian I. Rini, Moshe Chaim Ornstein, Tian Zhang · 2021 · Journal for ImmunoTherapy of Cancer
18. Polycomb repressive complex 2 and its core component EZH2: potential targeted therapeutic strategies for head and neck squamous cell carcinoma
    Yuxi Cheng, Zhengzheng Song, Xiaodan Fang, Zhangui Tang · 2024 · Clinical Epigenetics
19. Cancer immunotherapy clinical trials to support urgently needed access in low- and middle-income countries: a report from the SITC global access and impact committee
    Jennifer Dent, Micaella Jorge, Nora Sobrevilla, Thomas S. Uldrick, Innocent Adoubi, Jyoti Bajpai, Mauricio Burotto, Huwaida Bulhan, Gideon T. Dosunmu, Lilian Ekpo et al. · 2025 · Journal for ImmunoTherapy of Cancer
20. Cancer ecosystems: A dynamic interplay across scales
    Daniela F. Quail, Johanna A. Joyce · 2026 · Cell
21. Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overview
    Lothar Bergmann, Sarah Weber, Arndt Hartmann, Marit Ahrens · 2021 · Expert Review of Anticancer Therapy
22. From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit
    Toni K. Choueiri, Laurence K. Albiges, Michael B. Atkins, Ziad Bakouny, Gennady Bratslavsky, David A. Braun, Naomi Balzer Haas, John B.A.G. Haanen, A. Ari Hakimi, Michael A.S. Jewett et al. · 2021 · Clinical Cancer Research
23. The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: A systematic review and meta-analysis
    Keiichiro Mori, Fahad Quhal, Takafumi Yanagisawa, Satoshi Katayama, Benjamin Pradère, Ekaterina Laukhtina, Paweł Rajwa, Hadi Mostafaei, Reza Sari Motlagh, Takahiro Kimura et al. · 2022 · International Immunopharmacology
24. Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma
    Yuanquan Yang, Sarah P. Psutka, Anish B. Parikh, Mingjia Li, Katharine Ann Collier, Abdul Miah, Sherry Mori-Vogt, Megan Hinkley, Scott S. Tykodi, Evan Thomas Hall et al. · 2022 · Cancer Medicine
25. Iron accumulation typifies renal cell carcinoma tumorigenesis but abates with pathological progression, sarcomatoid dedifferentiation, and metastasis
    Christopher Greene, Kristopher M. Attwood, Nitika J. Sharma, Benjamin Balderman, Rongia Deng, Jason B. Muhitch, Gary J. Smith, Kenneth W. Gross, Bo Xu, ERIC C. KAUFFMAN · 2022 · Frontiers in Oncology
26. Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy
    Mohammadsaleh Jahangir, Omid Yazdani, Mohammad Saeed Kahrizi, Sara Soltanzadeh, Hamidreza Javididashtbayaz, Azam Mivefroshan, Saba Ilkhani, Romina Esbati · 2022 · Cancer Cell International
27. Biomarkers for Immune Checkpoint Inhibitors in Renal Cell Carcinoma
    Spencer D. Martin, Ishmam Bhuiyan, Maryam Soleimani, Gang Wang · 2023 · Journal of Clinical Medicine
28. Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases
    David A. Schoenfeld, Myrto K. Moutafi, Sandra Martinez, Dijana Djureinovic, Ross D. Merkin, Adebowale Adeniran, David A. Braun, Sabina Signoretti, Toni K. Choueiri, Fabio Parisi et al. · 2023 · Journal for ImmunoTherapy of Cancer
29. Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis
    Kinga Krawczyk, Katarzyna Śladowska, Przemysław Holko, Paweł Kawalec · 2023 · Frontiers in Pharmacology
30. Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review
    Laurence K. Albiges, Bradley Alexander McGregor, Daniel Y.C. Heng, Giuseppe Procopio, Guillermo de Velasco, Naila Taguieva-Pioger, Lidia Martín-Couce, Nizar M. Tannir, Thomas B. Powles · 2023 · Cancer Treatment Reviews
31. Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors
    Taymeyah Al‐Toubah, Michael J. Schell, Brian G. Morse, Mintallah Haider, Tiffany Valone, Jonathan Strosberg · 2024 · ESMO Open
32. The Frontline Immunotherapy-Based Treatment of Advanced Clear Cell Renal Cell Carcinoma: Current Evidence and Clinical Perspective
    In-Ho Kim, Hyo Jin Lee · 2022 · Biomedicines
33. Targeting the CD24-Siglec10 Axis: A Potential Strategy for Cancer Immunotherapy
    Junyue Fang, Lin Li, Yuan Cao, Jiabao Tan, Yixia Liang, Xiaoyun Xiao, Nengtai Ouyang, Phei Er Saw, Wei Yang · 2024 · BIO Integration
34. Clearing up Clear Cell: Clarifying the Immuno-Oncology Treatment Landscape for Metastatic Clear Cell RCC
    Sai Krishnaraya Doppalapudi, Zev Leopold, Akshay Thaper, Alain Kaldany, Kevin Joseph Chua, Hiren V. Patel, Arnav Srivastava, Eric A. Singer · 2021 · Cancers
35. Novel emerging biomarkers to immunotherapy in kidney cancer
    Yasser M. A. Ged, Martin Henner Voss · 2021 · Therapeutic Advances in Medical Oncology
36. Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial
    Thomas Denize, Subrina Farah, Alessia Cimadamore, Abdallah Flaifel, Emily Walton, Maura Aliezah Sticco-Ivins, Chris Labaki, David A. Braun, Maxine Sun, Evelyn W. Wang et al. · 2021 · Clinical Cancer Research
37. Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective study
    Taigo Kato, Kazutoshi Fujita, Takafumi Minami, Akira Nagahara, Yujiro Hyashi, Wataru Nakata, Kyosuke Matsuzaki, Kosuke Nakano, Koji Hatano, Atsunari Kawashima et al. · 2022 · International Journal of Clinical Oncology
38. Real world data on IO-based therapy for metastatic renal cell carcinoma
    Viktoria Stühler, Lisa Maria Herrmann, Steffen Rausch, Arnulf Stenzl, Jens Bedke · 2022 · Journal of Cancer Research and Clinical Oncology
39. Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System
    Emanuel Raschi, Michele Fusaroli, Valentina Giunchi, Andrea Repaci, Carla Pelusi, Veronica Mollica, Francesco Massari, Andrea Ardizzoni, Elisabetta Poluzzi, Uberto Pagotto et al. · 2022 · Cancers
40. Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab
    Yusuke Yano, Takaya Ohno, Kazumasa Komura, Wataru Fukuokaya, Taizo Uchimoto, Takahiro Adachi, Yosuke Hirasawa, Takeshi Hashimoto, Atsuhiko Yoshizawa, Shogo Yamazaki et al. · 2022 · Cancers
41. Complete Response in Metastatic Clear Cell Renal Cell Carcinoma Patients Treated with Immune-Checkpoint Inhibitors: Remission or Healing? How to Improve Patients’ Outcomes?
    Jonathan Thouvenin, Claire Masson, Philippe Boudier, Denis Maillet, Sabine Kuchler‐Bopp, Philippe Barthélémy, Thierry Massfelder · 2023 · Cancers
42. The role of immunotherapy in non-clear cell renal cell carcinoma
    Carla Climent, Sandra Soriano, Teresa Bonfill, Natalia Vila López, Marta Rodríguez-Castells, Marina Sierra, P. Andreu Cobo, Mónica Fragío Gil, Mireia Busquets, Alicia Carrasco et al. · 2023 · Frontiers in Oncology
43. Gut and urinary microbiota: the causes and potential treatment measures of renal cell carcinoma
    Jian-wei Yang, Shun Wan, Kunpeng Li, Siyu Chen, Li Yang · 2023 · Frontiers in Immunology
44. Targeting HIF-2 Alpha in Renal Cell Carcinoma
    Ramsha Ahmed, Moshe Chaim Ornstein · 2023 · Current Treatment Options in Oncology
45. Longitudinal Monitoring of Circulating Tumor DNA to Assess the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary Malignancies
    Albert Jang, Sree Maunika Lanka, Ellen Jaeger, Alexandra Lieberman, Minqi Huang, Oliver A. Sartor, Prateek Mendiratta, Jason Robert Brown, Jorge Alberto Garcia, Tiffany E. Farmer et al. · 2023 · JCO Precision Oncology
46. Patient-reported Outcome Measurement and Reporting for Patients with Advanced Renal Cell Carcinoma: A Systematic Literature Review
    Robert John Motzer, Pratik P. Rane, Todd L. Saretsky, Deepshikha Pawar, Allison Martin Nguyen, Murali Sundaram, Joseph E. Burgents, Rishabh Pandey, K. Rüdell · 2023 · European Urology
47. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
    Thomas B. Powles, Toni K. Choueiri, Robert John Motzer, Eric W. Jonasch, Sumanta Kumar Pal, Nizar M. Tannir, Sabina Signoretti, Rajesh Kaldate, Christian Scheffold, Evelyn W. Wang et al. · 2021 · BMC Cancer
48. Immune checkpoint inhibitors rechallenge in urological tumors: An extensive review of the literature
    Davide Bimbatti, Marco Maruzzo, Francesco Pierantoni, Alberto Diminutto, Michele Dionese, Filippo Maria Deppieri, Eleonora Lai, Vittorina Zagonel, Umberto Basso · 2022 · Critical Reviews in Oncology/Hematology
49. Severe tyrosine-kinase inhibitor induced liver injury in metastatic renal cell carcinoma patients: two case reports assessed for causality using the updated RUCAM and review of the literature
    Hana Študentová, Jindriska Volakova, Martina Spisarová, Anežka Zemánková, Květoslava Aiglová, Tomáš Szotkowski, Bohuslav Melichar · 2022 · BMC Gastroenterology
50. Incidence risk of peripheral edema in cancer patients treated with PD-1/PD-L1 inhibitors: A PRISMA guideline systematic review and meta-analysis
    Yuan Tian, Alan Huang, Mei Tian, Kaiyong Wang, Qi Dang, Wei Zhang, Hongmei Liu, Junyan Zhao, Xiaowei Yang, Chi Zhang et al. · 2022 · Medicine
51. Kidney cancer: From tumor biology to innovative therapeutics
    Laura Rinaldi, Emanuela Senatore, Stella Feliciello, Francesco Chiuso, Luigi Insabato, Antonio Feliciello · 2024 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
52. Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer
    Stefanie D. Krens, Nielka P. van Erp, Stefanie L. Groenland, Dirk Jan A. R. Moes, Sasja F. Mulder, Ingrid M.E. Desar, Tom van der Hulle, Neeltje Steeghs, Carla M.L. van Herpen · 2022 · BMC Cancer
53. Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis
    I. Kiss, M Kühn, Kristián Hrušák, Tomáš Büchler · 2022 · ESMO Open
54. A U.S. Food and Drug Administration–pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma
    Daniel Lee, Haley R Gittleman, Chana Weinstock, Daniel L. Suzman, Erik W. Bloomquist, Sundeep Agrawal, Michael Holman Brave, Jamie Leigh Brewer, Jaleh Fallah, Harpreet Singh et al. · 2023 · European Urology
55. Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: Trick or treat?
    Martina Catalano, Giuseppe Procopio, Pierangela Sepe, Matteo Santoni, Francesco Sessa, Donata Villari, Gabriella Nesi, Giandomenico Roviello · 2023 · Pharmacology & Therapeutics
56. SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma
    Xian-De Liu, Yan-ting Yann Zhang, Daniel James McGrail, Xuesong Zhang, Truong Lam, Anh G. Hoang, Elshad Hasanov, Ganiraju C. Manyam, Christine B. Peterson, Haifeng Zhu et al. · 2023 · Clinical Cancer Research
57. Overcoming Resistance Mechanisms to Immune Checkpoint Inhibitors: Leveraging the Anti-Tumor Immune Response
    Courtney H. Coschi, Rosalyn Anne Juergens · 2023 · Current Oncology
58. Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news
    Francisco Roque Zambrana, Lucía Carril-Ajuria, Alfonso Gómez de Liaño, Nieves Martínez Chanzá, Ray Manneh Kopp, Daniel Castellano, Guillermo de Velasco · 2021 · Cancer Treatment Reviews
59. Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis
    Carlo Cattrini, Carlo G. M. Messina, Chiara A. Airoldi, Sebastiano Buti, Giandomenico Roviello, Alessia Mennitto, Orazio Caffo, Alessandra Gennari, Melissa Bersanelli · 2021 · Therapeutic Advances in Urology
60. Antibody-drug conjugates: beyond current approvals and potential future strategies
    Siddharth Menon, Sagun Parakh, Andrew Mark Scott, Hui Kong Gan · 2022 · Exploration of Targeted Anti-tumor Therapy
61. The role of gut microbiome in immune modulation in metastatic renal cell carcinoma
    Jasna E. Deluce, Saman Maleki Vareki, Ricardo Fernandes · 2022 · Therapeutic Advances in Medical Oncology
62. Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma
    Robert Motzer, Toni K. Choueiri · 2021 · New England Journal of Medicine
63. Progress on angiogenic and antiangiogenic agents in the tumor microenvironment
    Jian Xu, Zhihua Tang · 2024 · Frontiers in Oncology
64. Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinoma
    Nicholas Salgia, Adil Khan, Wilhelm M. Aubrecht, Gavin Twoey, Jacky Chow, Kristopher M. Attwood, Han Yu, Jessie L Chiello, Nathaniel Fox Hansen, Brianna J. Wasik et al. · 2025 · Cancer Cell
65. Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma
    Yuki Nemoto, Hiroki Ishihara, Kazutaka Nakamura, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto et al. · 2021 · International Urology and Nephrology
66. Therapeutic targeting of VEGF and/or TGF-β to enhance anti-PD-(L)1 therapy: The evidence from clinical trials
    Linwei Li, Qinglian Wen, Ruilin Ding · 2022 · Frontiers in Oncology
67. Current therapeutic options for glioblastoma and future perspectives
    Elisa Aquilanti, Patrick Yung Wen · 2022 · Expert Opinion on Pharmacotherapy
68. Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance
    David A. Schoenfeld, Ross D. Merkin, Myrto K. Moutafi, Sandra Martinez, Adebowale Adeniran, Deepika Kumar, Lucia B. Jilaveanu, Michael E. Hurwitz, David L. Rimm, Harriet M. Kluger · 2022 · Frontiers in Oncology
69. Treatment of Refractory Metastatic Renal Cell Carcinoma
    Joseph A. Vento, Brian I. Rini · 2022 · Cancers
70. An Update on the Treatment of Papillary Renal Cell Carcinoma
    Neal Shiv Chawla, Nicolas Sayegh, Sweta R. Prajapati, Elyse H. Chan, Sumanta Kumar Pal, Alex Chehrazi‐Raffle · 2023 · Cancers
71. Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature
    Alexius John, Lavinia Anne Spain, Anis Hamid · 2023 · Current Oncology
72. The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study
    Koji Iinuma, Toyohiro Yamada, Koji Kameyama, Tomoki Taniguchi, Kei Kawada, Takashi Ishida, Shingo Nagai, Torai Enomoto, Shota Ueda, Kimiaki Takagi et al. · 2023 · Cancers
73. Patient-reported outcomes in metastatic renal cell carcinoma trials using combinations versus sunitinib as first-line treatment
    Kyle M. Nolla, David Joseph Benjamin, David F Cella · 2023 · Nature Reviews Urology
74. Comparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional Study
    Hiroki Ishihara, Yuki Nemoto, Kazutaka Nakamura, Hidekazu Tachibana, Takashi Ikeda, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura et al. · 2023 · Targeted Oncology
75. The components of tumor microenvironment as biomarker for immunotherapy in metastatic renal cell carcinoma
    Jiaming Su, Lu Zhou, Zhe Zhang, Xue Xiao, Yanning Qin, Xiaoying Zhou, Tingting Huang · 2023 · Frontiers in Immunology
76. Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma: Current Evidence and Future Directions
    Enrico Sammarco, Fiorella Manfredi, Amedeo Nuzzo, Marco Ferrari, Adele Bonato, Alessia Salfi, Debora Serafin, Luca Zatteri, Andrea Antonuzzo, Luca Galli · 2023 · Cancers
77. Inter- and intra-tumor heterogeneity of genetic and immune profiles in inherited renal cell carcinoma
    Mariko Tabata, Yusuke Sato, Yasunori Kogure, Marni B. McClure, Yuji Oshikawa-Kumade, Yuki Saito, Sumito Shingaki, Yuta Ito, Mitsuhiro Yuasa, Junji Koya et al. · 2023 · Cell Reports
78. A multicentric, single arm, open-label, phase I/II study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer (PRadR)
    David Kryza, Armelle Vinceneux, Anne-Sophie Bidaux, Gwenaëlle Garin, Delphine Tatu, Claire Cropet, Jean‐Noël Badel, David Pérol, Anne‐Laure Giraudet · 2024 · BMC Cancer
79. Efficacy and toxicity of immune checkpoint inhibitors combination therapy for advanced renal cell carcinoma: a systematic review and network meta-analysis
    Xiangyu Chen, Zhunan Xu, Changgui Wu, Lijun Xie, Pengyu Wang, Xiaoqiang Liu · 2024 · Frontiers in Immunology
80. Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma
    Lucía Carril-Ajuria, Pernelle Lavaud, Cécile Dalban, Sylvie Négrier, Gwénaëlle Gravis, Robert John Motzer, Christine Chevreau, Nizar M. Tannir, Stéphane Marie. Oudard, David F. McDermott et al. · 2024 · European Journal of Cancer
81. Longitudinal Testing of Circulating Tumor DNA in Patients With Metastatic Renal Cell Carcinoma
    Arnab Basu, Cherry Au, Ajitha Kommalapati, Hyndavi Kandala, Sumedha Sudhaman, Tamara Mahmood, Carcia Carson, Natalia Pajak, Punashi Dutta, Mark A. Calhoun et al. · 2024 · JCO Precision Oncology
82. Clinical benefit of immune checkpoint inhibitors in elderly cancer patients: Current evidence from immunosenescence pathophysiology to clinical trial results
    Dimitrios C. Ziogas, Charalampos Theocharopoulos, Katerina Aravantinou-Fatorou, Aristeidis E. Boukouris, Dimitra T. Stefanou, Amalia N. Anastasopoulou, Peter Lialios, George Lyrarakis, Helen J Gogas · 2025 · Critical Reviews in Oncology/Hematology
83. A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01)
    Scott, Aaron J., Basu Mallick, Atrayee, Dotan, Efrat, Cohen, Steven J., Gold, Philip J., Hochster, Howard S., Subramaniam, Somasundaram, Barzi, Afsaneh, Watts, George S., Blatchford, Patrick J. et al. · 2022 · Cancer Research Communications
84. Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a US Food and Drug Administration pooled analysis
    Jaleh Fallah, Haley R Gittleman, Chana Weinstock, Elaine Chang, Sundeep Agrawal, Shenghui W. Tang, Richard Pazdur, Paul Gustav Kluetz, Daniel L. Suzman, Laleh Amiri‐Kordestani · 2024 · JNCI Journal of the National Cancer Institute
85. Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma
    Neeraj Agarwal, James Brugarolas, Pooja Ghatalia, S. George, John B.A.G. Haanen, Howard Gurney, Rahul Ravilla, Astrid Aplonia Maria Van Der Veldt, Benoit Beuselinck, Илья Анатольевич Покатаев et al. · 2024 · Annals of Oncology
86. Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study
    Camillo Porta, Francesco Massari, Tarek Taha, Enrique Grande, Maria Teresa Bourlon, Ravindran Kanesvaran, Umberto Basso, Javier Molina‐Cerrillo, Teresa Alonso‐Gordoa, Zin War Myint et al. · 2025 · Cancer Immunology Immunotherapy
87. Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma
    Vishal Navani, Matthew Scott Ernst, John Connor Wells, Takeshi Yuasa, Kosuke null Takemura, Frede N. Donskov, Naveen S. Basappa, Andrew Lachlan Schmidt, Sumanta Kumar Pal, Luís Meza et al. · 2022 · JAMA Network Open
88. Management of Immune-Related Adverse Events from Immune-Checkpoint Inhibitors in Advanced or Metastatic Renal Cell Carcinoma
    Katharina Leucht, Nalyan Ali, Susan Foller, Marc‐Oliver Grimm · 2022 · Cancers
89. Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial
    Andrea Borghese Apolo, Thomas B. Powles, Bernard J. Escudier, Mauricio Burotto, Joshua H. Zhang, Burçin Şimşek, Christian Scheffold, Robert John Motzer, Toni K. Choueiri · 2022 · European Journal of Cancer
90. IO-IO vs IO-TKI efficacy in metastatic kidney cancer patients: A structured systematic review over time
    Benedikt Hoeh, Rocco Simone Flammia, Lukas Hohenhorst, Gabriele Sorce, Andrea Panunzio, Stefano Tappero, Zhe Tian, Fred Saad C, Michele Gallucci, Alberto Briganti et al. · 2022 · Seminars in Oncology
91. Review and prospect of immune checkpoint blockade therapy represented by PD-1/PD-L1 in the treatment of clear cell renal cell carcinoma
    Wenfei Ge, Shiyan Song, Xiaochen Qi, Feng Chen, Xiangyu Che, Yonghao Sun, Jin Wang, Xiaowei Li, Nana Liu, Qifei Wang et al. · 2023 · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
92. Understanding and integrating cytoreductive nephrectomy with immune checkpoint inhibitors in the management of metastatic RCC
    Arighno Das, Daniel D. Shapiro, Juliana K. Craig, Edwin Jason Abel · 2023 · Nature Reviews Urology
93. An Overview of Systemic Targeted Therapy in Renal Cell Carcinoma, with a Focus on Metastatic Renal Cell Carcinoma and Brain Metastases
    Liliana Eleonora Semenescu, Amira Kamel, Vasile Gheorghe Ciubotaru, Silvia Mara Baez Rodriguez, Adrian Mircea Fürtös, Alexandra Costachi, Anica Dricu, Ligia Gabriela Tătăranu · 2023 · Current Issues in Molecular Biology
94. Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001
    Christopher Montemagno, Arnaud Jacquel, Charlotte Pandiani, Olivia Rastoin, Rosie Dawaliby, Thomas Schmitt, Maxence Bourgoin, Héliciane Palenzuela, Anne-Laure Rossi, Damien Ambrosetti et al. · 2024 · Journal of Experimental & Clinical Cancer Research
95. Renal Cell Carcinoma of Variant Histology: New Biologic Understanding Leads to Therapeutic Advances
    Nicholas Salgia, Zeynep Büşra Zengin, Sumanta Kumar Pal, Nazlı Dizman · 2024 · American Society of Clinical Oncology Educational Book
96. Malignant Pleural Effusion: A Multidisciplinary Approach
    Ana Pardessus, A Rafecas, José Manuel Porcel, Pere Serra, Lucía Ferreiro, Maribel Botana‐Rial, Cristina Ramos Hernández, Jose Manuel Brenes, Lydia Canales, Valle Camacho et al. · 2024 · Open Respiratory Archives
97. Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trial
    Mehmet Asım Bilen, Baohan Thi Vo, Yuan Liu, Rachel Greenwald, Amir H. Davarpanah, Donald J. McGuire, Rakesh Shiradkar, Liping Li, Adhishek Midya, Bassel Nazha et al. · 2025 · Nature Cancer
98. Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis
    Keiichiro Mori, Benjamin Pradère, Fahad Quhal, Satoshi Katayama, Hadi Mostafaei, Ekaterina Laukhtina, Victor M. Schuettfort, David D’Andrea, Shin Egawa, Karim Bensalah et al. · 2021 · Cancer Treatment Reviews
99. Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors
    Daniel Schlauch, Xiaotong Fu, Suzanne Fields Jones, Howard A. Burris, David Robert Spigel, James Andrew Reeves, Andrew Jacob McKenzie · 2021 · JCO Precision Oncology
100. Combination therapy patents: a new front in evergreening
     Garth William Strohbehn, Alec J. Kacew, Daniel A. Goldstein, Robin Feldman, Mark J. Ratain · 2021 · Nature Biotechnology